[New therapy with monoclonal antibodies--abciximab, chimeric anti-GP IIb/IIIa antibody].
Platelet aggregation is now believed to be mediated by fibrinogen binding to activated GP IIb/IIIa. Antigen binding site of mouse anti-human GP IIb/IIIa monoclonal antibody 7E3, which can inhibit fibrinogen binding to activated human platelet GP IIb/IIIa, was combined with constant region of human IgG to reduce immunogenicity. Monovalent Fab of this mouse-human chimeric antibody named abciximab effectively reduced the onset of cardiovascular accidents when administered in combination with heparin and aspirin in patients undergoing coronary interventions. Although several anti-GP IIb/IIIa other than monoclonal antibodies were developed, clinical efficiency of abciximab is still superior to other agents while its effects on preventing myocardial infarction in unstable angina patients are uncertain.
Goto
Shinya
S
Division of Cardiology, Department of Medicine, Tokai University School of Medicine.
D000077284:Abciximab; D000789:Angina, Unstable / Q000209:etiology / Q000517:prevention & control; D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects; D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D003327:Coronary Disease / Q000628:therapy; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000627:therapeutic use; D051379:Mice; D009203:Myocardial Infarction / Q000209:etiology / Q000517:prevention & control; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000276:immunology; D011993:Recombinant Fusion Proteins
D000911:Antibodies, Monoclonal; D007140:Immunoglobulin Fab Fragments; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D011993:Recombinant Fusion Proteins; D000077284:Abciximab